Teleflex Incorporated logo

Teleflex Incorporated

TFX

NYSEHealthcareMedical - Instruments & Supplies

Previous close

$138.83

+$3.87 · +2.87%

Aug 21, 4:00 PM ET

TFX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

54

Fair Value

Momentum

50

Neutral

Sentiment

68

Bullish

Risk resilience

76

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Jason Weidman
Listed since
Mar 17, 1980
Employees
15,500

Market position

Day range

Current $138.83

52-week range

Current $138.83

Open
$133.31
Previous close
$134.96
Volume
630.89K
0.94× average
Average volume
672.47K
Average daily volume
Market cap
6.15B USD
Beta
0.81
Market reference 1
50-day average
$132.65
+4.66% above average
200-day average
$121.75
+14.03% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
7.78B USD
P/E (TTM)
-5.96×
P/B (TTM)
2.08×
P/S (TTM)
2.36×
EV / EBITDA
25.71×
Earnings yield
-16.63%
Free cash flow yield
4.51%
Dividend yield
0.98%

Profitability & efficiency

Gross margin
53.77%
Operating margin
3.35%
Net margin
-39.58%
Return on equity
-28.98%
Return on assets
-13.04%
Return on invested capital
4.07%

Financial health

Debt / equity
0.99×
Current ratio
2.54×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends66%26%-15%-56%Gross margin, FY2021: 55.15%Gross margin, FY2022: 54.86%Gross margin, FY2023: 55.37%Gross margin, FY2024: 55.87%Gross margin, FY2025: 56.24%Operating margin, FY2021: 22.36%Operating margin, FY2022: 17.90%Operating margin, FY2023: 17.02%Operating margin, FY2024: 4.96%Operating margin, FY2025: 12.84%Net margin, FY2021: 17.28%Net margin, FY2022: 13.01%Net margin, FY2023: 11.98%Net margin, FY2024: 2.29%Net margin, FY2025: -45.45%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 55.15%. Gross margin FY2022 54.86%. Gross margin FY2023 55.37%. Gross margin FY2024 55.87%. Gross margin FY2025 56.24%. Operating margin FY2021 22.36%. Operating margin FY2022 17.90%. Operating margin FY2023 17.02%. Operating margin FY2024 4.96%. Operating margin FY2025 12.84%. Net margin FY2021 17.28%. Net margin FY2022 13.01%. Net margin FY2023 11.98%. Net margin FY2024 2.29%. Net margin FY2025 -45.45%.

Income trends

Revenue

1.99B USD-34.61%

Operating income

255.8M USD+69.39%

Net income

−905.64M USD−975.32M USD
Income trends across reported periods3.44B USD1.86B USD280.25M USD−1.3B USDRevenue, FY2021: 2.81B USDRevenue, FY2022: 2.79B USDRevenue, FY2023: 2.97B USDRevenue, FY2024: 3.05B USDRevenue, FY2025: 1.99B USDOperating income, FY2021: 628.1M USDOperating income, FY2022: 499.73M USDOperating income, FY2023: 506.31M USDOperating income, FY2024: 151.01M USDOperating income, FY2025: 255.8M USDNet income, FY2021: 485.37M USDNet income, FY2022: 363.14M USDNet income, FY2023: 356.33M USDNet income, FY2024: 69.68M USDNet income, FY2025: −905.64M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.81B USD. Revenue FY2022 2.79B USD. Revenue FY2023 2.97B USD. Revenue FY2024 3.05B USD. Revenue FY2025 1.99B USD. Operating income FY2021 628.1M USD. Operating income FY2022 499.73M USD. Operating income FY2023 506.31M USD. Operating income FY2024 151.01M USD. Operating income FY2025 255.8M USD. Net income FY2021 485.37M USD. Net income FY2022 363.14M USD. Net income FY2023 356.33M USD. Net income FY2024 69.68M USD. Net income FY2025 −905.64M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.99B USD3.05B USD2.97B USD2.79B USD2.81B USD
Cost of goods sold871.96M USD1.34B USD1.33B USD1.26B USD1.26B USD
Gross profit1.12B USD1.7B USD1.65B USD1.53B USD1.55B USD
Research and development144.78M USD161.67M USD154.35M USD153.82M USD130.84M USD
Selling, general, and administrative720.17M USD995.27M USD929.87M USD863.75M USD860.09M USD
Operating expenses864.95M USD1.55B USD1.14B USD1.03B USD921.51M USD
Interest income6.4M USD8.01M USD12.78M USD912K USD1.33M USD
Interest expense100.22M USD83.54M USD85.08M USD54.26M USD56.97M USD
Depreciation and amortization177.74M USD274.6M USD242.12M USD230.59M USD237.36M USD
Operating income255.8M USD151.01M USD506.31M USD499.73M USD628.1M USD
Net income−905.64M USD69.68M USD356.33M USD363.14M USD485.37M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+3.61%
11 comparable reports
Latest EPS result
1.76
Estimate 1.28 · Beat by 37.50%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates4.13.082.051.03Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 3.89, estimate 3.86, surprise +0.78%, Beat. Q2 2025, reported May 1, 2025: actual 2.91, estimate 2.88, surprise +1.04%, Beat. Q3 2025, reported Jul 31, 2025: actual 3.73, estimate 3.36, surprise +11.01%, Beat. Q4 2025, reported Nov 6, 2025: actual 3.67, estimate 3.38, surprise +8.58%, Beat. Q1 2026, reported Feb 26, 2026: actual 1.93, estimate 3.73, surprise -48.26%, Miss. Q2 2026, reported May 7, 2026: actual 1.39, estimate 1.21, surprise +14.88%, Beat. Q3 2026, reported Aug 6, 2026: actual 1.76, estimate 1.28, surprise +37.50%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.89, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates956.09M804.1M652.12M500.13MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 795.41M USD, estimate 767.14M USD, surprise +3.68%, Beat. Q2 2025, reported May 1, 2025: actual 700.67M USD, estimate 766.13M USD, surprise -8.54%, Miss. Q3 2025, reported Jul 31, 2025: actual 780.89M USD, estimate 892.93M USD, surprise -12.55%, Miss. Q4 2025, reported Nov 6, 2025: actual 913.02M USD, estimate 914.95M USD, surprise -0.21%, Miss. Q1 2026, reported Feb 26, 2026: actual 569M USD, estimate 919.31M USD, surprise -38.11%, Miss. Q2 2026, reported May 7, 2026: actual 548.26M USD, estimate 536.91M USD, surprise +2.11%, Beat. Q3 2026, reported Aug 6, 2026: actual 570.3M USD, estimate 559.59M USD, surprise +1.91%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 565.37M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

29 ratings
Strong buy00%
Buy1552%
Hold1345%
Sell13%
Strong sell00%

Recent analyst actions

12 institutions
UBSmaintainNeutral

TFX peers

ETFs holding TFX

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research TFX

research.disclaimer